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We have previously detected two related murine nuclear proteins, p160 and p67, that can bind to the leucine
zipper motif within the negative regulatory domain of the Myb transcription factor. We now describe the
molecular cloning of cDNA corresponding to murine p160. The P160 gene is located on mouse chromosome 11,
and related sequences are found on chromosomes 1 and 12. The predicted p160 protein is novel, and in
agreement with previous studies, we find that the corresponding 4.5-kb mRNA is ubiquitously expressed. We
showed that p67 is an N-terminal fragment of p160 which is generated by proteolytic cleavage in certain cell
types. The protein encoded by the cloned p160 cDNA and an engineered protein (p67*) comprising the
amino-terminal region of p160 exhibit binding specificities for the Myb and Jun leucine zipper regions identical
to those of endogenous p160 and p67, respectively. This implies that the Myb-binding site of p160 lies within
the N-terminal 580 residues and that the Jun-binding site is C-terminal to this position. Moreover, we show
that p67* but not p160 can inhibit transactivation by Myb. Unexpectedly, immunofluorescence studies show
that p160 is localized predominantly in the nucleolus. The implications of these results for possible functions
of p160 are discussed.
It is becoming increasingly clear that c-myb plays an essential
role in controlling the proliferation and differentiation of he-
matopoietic cells. This was first suggested on the basis of its
preferential expression in immature hematopoietic cells and
the subsequent decrease in expression on differentiation (25,
70). Confirmation has been provided by more recent loss-of-
function studies involving targeted disruption of c-myb, which
results in the abrupt failure of development of the fetal hema-
topoietic system (50), and by the ability of antisense oligonu-
cleotides to inhibit the proliferation of both normal and trans-
formed hematopoietic cells (1, 21). Furthermore, enforced
expression of activated (23, 28) and normal (18) forms of c-myb
can transform hematopoietic cells in vitro (but not, in general,
other cell types) and inhibit the induced differentiation of
certain leukemic cell lines (8, 11, 72). Taken together, these
data suggest that one major function of c-myb is to maintain
the proliferative state and immature characteristics of early
hematopoietic cells.
The proteins encoded by normal and oncogenically activated
myb genes (Myb) are transcription factors; i.e., they bind to
specific DNA sequences (7) and can enhance transcription of
genes and reporter constructs carrying Myb binding sites (53,
54, 71). These functions are also essential for the ability of myb
oncogenes to transform hematopoietic cells (34, 43). Onco-
genically activated forms of Myb differ from normal c-Myb in
that they are truncated at either their amino termini, their
carboxyl termini, or both (22, 64). Carboxyl truncation acti-
vates c-Myb by disrupting or deleting a region—termed the
negative regulatory domain (NRD)—which appears to down-
modulate transactivation, DNA binding, and transformation
(15, 34, 58, 62).
One significant clue to how the NRD exerts its effects on
Myb function comes from the observation that the NRD con-
tains a leucine zipper-like motif (7) and that disruption of this
motif by point mutations enhances transactivation and trans-
formation (38). Because leucine zippers generally mediate pro-
tein-protein interactions, it seems likely that the Myb leucine
zipper promotes association between c-Myb and another pro-
tein which inhibits Myb function. There is ample precedent for
the existence of protein inhibitors of transcription factors, in-
cluding Id (6), and IkB (5), which antagonize the function of
MyoD and NF-kB, respectively. Alternatively, the Myb inhib-
itory protein could be c-Myb itself, since the leucine zipper is
capable of mediating homodimerization and since Myb ho-
modimers are ineffective in DNA binding or transactivation
(55). In this scenario, dimerization may be modulated by com-
petition with another protein capable of forming heterodimers;
this latter protein would then function as an activator of Myb.
In either case, understanding the regulation of Myb activity
would clearly be aided by the identification and characteriza-
tion of proteins which interact with the c-Myb leucine zipper.
We have previously described two murine proteins, termed
p67 and p160 (17), that can bind to the c-Myb leucine zipper.
These were identified by using a bacterially expressed fusion
protein containing the Myb leucine zipper region as an affinity
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reagent to capture proteins from radiolabelled nuclear ex-
tracts. Their specificity was demonstrated by the observation
that they do not bind to similar fusion proteins in which two of
the critical leucine residues were replaced with proline or ala-
nine residues. Although peptide mapping revealed that p67
and p160 are closely related, there are (at least) two important
differences. First, p160, but not p67, can also bind to the c-Jun
basic leucine zipper (bZip) region, suggesting that it may be
involved in the regulation of other transcription factors in
addition to c-Myb. Second, p160 is expressed in all the murine
cell lines we have studied to date, whereas p67 was found only
in a subset of early myeloid lines (17).
In this paper, we report the molecular cloning of cDNA
sequences corresponding to murine p160. The predicted amino
acid sequence indicates that p160 appears to be a novel pro-
tein. We have used the p160 cDNA to examine the relationship
between p160 and p67; we find that p67 represents the amino
(N)-terminal region of p160 and is generated by proteolytic
cleavage. We further demonstrate that the cloned p160 can
specifically associate with Myb and that a truncated form of
p160, which retains its only N-terminal region, can inhibit
transactivation by Myb. Immunofluorescence studies of the
p160 protein show, surprisingly, that most of the protein is
present in the nucleolus. This finding draws attention to some
interesting parallels with other nucleolar proteins and, to-
gether with our other findings, suggests possible functions for
p160 and p67.
MATERIALS AND METHODS
Purification of p67. Nuclear extracts were prepared from approximately 1010
FDC-P1 cells by a scaled-up version of the protocol described in reference 17
(see also reference 24). FDC-P1 cells were grown in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal calf serum and 50 U of mouse granulo-
cyte-macrophage colony-stimulating factor per ml (kindly supplied by Tracy
Wilson, Walter and Eliza Hall Institute, Melbourne, Australia) to a density of
1 3 106 to 2 3 106 cells/ml. The nuclear extract was divided into two 50-ml
aliquots and precleared successively with 2 ml of glutathione-Sepharose (Phar-
macia), 1.25 ml of glutathione S-transferase (GST)-Sepharose (;8 mg of pro-
tein), and 1.25 ml of GST-L34P Myb-Sepharose (17) (;2 mg of protein), each
with rotation for 1 h at 4°C. The precleared supernatant was incubated with 1.5
ml of GST-NRD2-Sepharose (17) (;2 mg of protein) as above to isolate p67.
The Sepharose matrix and bound proteins were washed five times with 10 ml of
cold NETN buffer (20 mM Tris-HCl [pH 8.0], 100 mM NaCl, 1 mM EDTA, 0.5%
Nonidet P-40 [NP-40]) and twice with 10 ml of cold phosphate-buffered saline
(PBS)–0.5% Triton X-100. Bound proteins were eluted with two washes of 1.5 ml
of DOC buffer (100 mM NaCl, 50 mM Tris-HCl [pH 8.0], 1% deoxycholic acid,
1% NP-40, 5 mM dithiothreitol [DTT]) and concentrated (;100 ml) on a Cen-
tricon-30 column (Amicon). The concentrated protein was separated by electro-
phoresis in a sodium dodecyl sulfate SDS-8% polyacrylamide gel, and stained
with CBR-250 to visualize proteins. The p67 protein band was excised from the
gel and subjected to in-gel proteolysis.
In-gel protein digestion and amino acid sequence analysis. In-gel proteolysis
of acrylamide gel-resolved proteins was performed essentially as described pre-
viously (49, 61). Tryptic peptides extracted from acrylamide gel pieces with
trifluoroacetic acid-acetonitrile were fractionated by rapid reverse-phase high-
pressure liquid chromatography on a Brownlee RP-300 cartridge (2.1 mm by 100
mm; Applied Biosystems, Foster City, Calif.) with a Hewlett-Packard 1090A
liquid chromatograph fitted with a model 1040A diode-array detector as de-
scribed previously (49). N-terminal amino acid sequence analysis of peptides was
performed by automated Edman degradation with a Hewlett-Packard (model
G1005A) protein sequencer operating with the routine 1.3 sequencer program. A
Hewlett-Packard model HP1090M liquid chromatograph was used for phenyl-
thiohydantoin amino acid analysis (49). The following five peptide sequences
were obtained: PDQETRLAT(E) (peptide 1), VILRSPK (peptide 2), VLEEG
(STGR) (peptide 3), VDHLHLEK (peptide 4), and ATPQIPETK (peptide 5);
the residues shown in parentheses were ambiguous and in fact are not found in
the predicted p67/p160 sequence (see Results and Fig. 1).
Degenerate oligonucleotides and library screening. Degenerate oligonucleo-
tides were derived from four of the p67 partial tryptic peptide sequences (see Fig.
1B) and used in various combinations to amplify FDC-P1 cDNA by PCR.
First-strand cDNA was synthesized from FDC-P1 poly(A)1 RNA (4 mg) with an
oligo(dT18) primer and SuperScript reverse transcriptase (Gibco BRL) as de-
scribed previously (60). Degenerate oligonucleotides corresponding to peptide 4
[59-ATAGGATCCGA(C/T)CA(C/T)(C/T)T(C/T/G)CA(C/T)(C/T)T(C/T/G)G
A(A/G)AA-39], incorporating a BamHI, site and peptide 5 [59-AGGAATTCC
TT(T/G/A)GT(T/C)TC(T/G/A)GG(G/A/T)AT(T/C)TG(T/G/A)GG-39], incor-
porating an EcoRI site, yielded an amplification product of 114 bp under the
following PCR conditions: 94°C for 1 min, 56°C for 2 min, and 72°C for 2 min for
35 cycles. The 114-bp product was digested with BamHI-EcoRI, cloned into
pGEM-4Z (Promega), and sequenced. DNA from a WEHI-3B cDNA Lambda
Zap library (Stratagene) was used to obtain a 459-bp PCR product by using the
T3 RNA polymerase promoter sequence and a primer derived from the initial
114-bp cDNA sequence: 59-ATAGGATCCTCGTCTTAAAGAAGGCATG
G-39 (94°C for 30 s, 58°C for 2 min, and 72°C for 3 min for 35 cycles). The 459-bp
product was digested with BamHI, cloned into pBluescript SK (Stratagene), and
verified by DNA sequencing. The same WEHI-3B cDNA Lambda Zap library
(Stratagene) was screened by plaque hybridization with the 459-bp cDNA se-
quence as specified by the manufacturer. A positive plaque was identified, and a
3.1-kbp cDNA clone was obtained by excision of pBluescript SK from the
UNI-ZAP XR vector as specified by the manufacturer. This cDNA clone was
sequenced by first generating a unidirectional deletion series with the Erase-a-
Base system (Promega) as specified by the manufacturer and then sequencing
several of the deleted clones.
5* RACE PCR. 59 rapid amplification of DNA ends (RACE) PCR (19) was
performed by the method used with the 59-AmpliFINDER kit (Clontech). First-
strand cDNA was synthesized from FDC-P1 poly(A)1 RNA (2 mg) with a p160
cDNA-derived oligonucleotide (59-TTGTAAAGGCCACCATCATAGTCAAC
TGCC-39) and SuperScript reverse transcriptase (Gibco BRL) as described pre-
viously (60). 59 RACE PCR was undertaken with a p160 gene-specific primer,
incorporating a BamHI site (59-CGGATCCGGAAGGTACCCACGTATG-39)
and the AmpliFINDER anchor primer (Clontech) under the following condi-
tions: 94°C for 45 s, 60°C for 1 min, and 72°C for 2 min for 30 cycles. The
resulting PCR product was digested with EcoRI-BamHI, cloned into pBluescript
SK (Stratagene), and verified by DNA sequencing.
Construction of plasmids. A full-length p160 cDNA clone was constructed in
pGEM-3Z (Promega) by using the unique KpnI site present in both the 59 RACE
PCR product and the 3.1-kbp partial p160 cDNA clone (nucleotides 992 to
4126). Partial p160 cDNA in pBluescript (Stratagene) was digested with EcoRI-
XhoI and subcloned into the EcoRI-SalI sites of pGEM-3Z. This construct was
subsequently digested with EcoRI-KpnI and ligated with the 59 RACE PCR
EcoRI-KpnI fragment to yield a full-length p160 cDNA clone (pGEM3Z-160).
The p67* cDNA construct was derived from p160 cDNA by introducing a
termination codon after nucleotide position 1755 by PCR to yield a protein with
a predicted molecular mass of approximately 67 kDa. The following PCR prim-
ers were used to generate the p67* cDNA clone: 59-TATCGAATTCGTGACG
TGTTTGGCTCAGC-39 and 59-ACGTGGATCCTCATTCCTTCAGAGTACT
C-39, incorporating a BamHI site (94°C for 45 s, 60°C for 1 min, and 72°C for 90 s
for 30 cycles). The resulting PCR product was digested with EcoRI-BamHI and
cloned into pGEM-3Z to yield pGEM3Z-67*. Two GST fusion constructs con-
taining 59 or 39 p160 sequences were made as follows. The 59 p160 fragment
(nucleotides 1 to 1083) was generated by digestion of pGEM3Z-160 with EcoRI-
KpnI, blunt ended, and ligated into the SmaI site of pGEX-4T-1 (Pharmacia).
The 39 p160 fragment (nucleotides 3151 to 4101) was generated by digestion of
partial p160 cDNA in pBluescript (Stratagene) with BamHI-SspI, blunt ended,
and ligated into the SmaI site of pGEX-3X (Pharmacia). The in-frame GST-
p160 sequences were verified by DNA sequencing.
Site-directed mutagenesis and construction of expression vectors. The FLAG
epitope (DYKDDDDK) was introduced into the amino termini of p160 and
p67* by in vitro site-directed mutagenesis with the pALTER-1 system (Promega)
as specified by the manufacturer. The mutagenic oligonucleotides for both p160
and p67* cDNAs incorporated the FLAG octapeptide sequence downstream of
a Kozak consensus initiation site, with the original translation initiation site
replaced. The presence of the mutagenized sequences was verified by DNA
sequencing.
The FLAG epitope-tagged p160 and p67* expression plasmids were con-
structed from the pact-c-myb expression vector (described in reference 54) by
first excising the c-myb cDNA by digestion with NcoI-XbaI. This was replaced by
an NcoI-XbaI fragment containing FLAG p67* cDNA to yield pact-67*FLAG.
pact-160FLAG was constructed by generating a fragment containing FLAG p160
cDNA by PCR from the pALTER-1-p160FLAG plasmid with the SP6 RNA
polymerase promoter sequence and 59-ACGTACTAGTTCAAGGTGTCTGCA
CTCTC-39 (94°C for 45 s, 50°C for 1 min, and 72°C for 4 min for 30 cycles),
digestion with NcoI-SpeI, and replacement of the c-myb gene between the NcoI/
XbaI sites of pact-c-myb.
The retroviral construct containing p160FLAG cDNA was generated by di-
gestion of the pALTER-1-p160FLAG plasmid with EcoRI-SalI, blunt-ended,
and ligated into the HpaI site of pRUFneo (60).
In vitro transcription-translation. Proteins were synthesized in vitro by using
the TNT coupled transcription-translation rabbit reticulocyte lysate kit (Pro-
mega). Briefly, 1 mg each of pGEM3Z-160 and pGEM3Z-67* was incubated at
30°C for 90 min in a 50-ml reaction volume containing the recommended quan-
tities of kit reagents, including T7 RNA polymerase and 4 ml of translation grade
[35S]methionine (10.2 mCi/ml; NEN Dupont). Labelled proteins were analyzed
by SDS-polyacrylamide gel electrophoresis (PAGE) and detected by autoradiog-
raphy with Hyperfilm-MP (Amersham).
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Proteolysis by cell extracts. Extracts were made by suspending cells at 108/ml
in 25 mM HEPES (pH 7.4)–1 mM EDTA–0.1% 3-[(3-cholamidopropyl)-dim-
ethylammonio]-1-propanesulfonate (CHAPS)–10% sucrose–5 mM DTT. The
cells were lysed with three cycles of freezing in liquid nitrogen and thawing at
37°C and then centrifuged at 1,000 rpm (Heraeus Biofuge 13) for 5 min at 4°C.
The supernatant was clarified by centrifugation at 13,000 rpm (Heraeus Biofuge
13) for 15 min and stored at 220°C. Proteolysis reactions were carried out with
10 mg of extract, 10 ml of in vitro-translated [35S]methionine-labelled p160, plus
buffer in a total volume of 30 ml, and the reaction mixtures were incubated at
37°C for various periods before the reactions were terminated by adding 23 SDS
loading buffer; the products were analyzed by SDS-PAGE.
Southern blotting analysis. Genomic DNA was isolated from FDC-P1 cells as
described previously (2), except that the DNA was spooled onto a Pasteur
pipette rather than pelleted. DNA was digested with restriction enzymes, frac-
tionated by electrophoresis in a 1% agarose gel, and transferred to Hybond-N
nylon membrane (Amersham) as specified by the manufacturer. Southern blots
were probed with 59 (nucleotides 1 to 1083) and 39 (nucleotides 3151 to 4101)
p160 cDNA sequences and labelled with [a-32P]dATP by using a random primer
labelling kit (Amersham). Hybridizations were performed as described previ-
ously (63) at the following stringency: 50% formamide–53 SSC (13 SSC is 0.15
M NaCl plus 0.015 M sodium citrate) at 42°C. The blots were washed with 23
SSC–0.1% SDS at 60°C.
Chromosomal localization. Interspecific mouse backcross mapping was used
to determine the chromosomal locations of p160 sequences. Backcross progeny
were generated by mating (C57BL/6J 3 Mus spretus)F1 females and C57BL/6J
males as described previously (12). A total of 205 N2 mice were used to map the
p160 loci (see Fig. 2B). DNA isolation, restriction enzyme digestion, agarose gel
electrophoresis, Southern blot transfer, and hybridization were performed es-
sentially as described previously (37). All the blots were prepared with Zetabind
nylon membrane (AMF Cuno). The 39 p160 cDNA probe used is the same as
that described in the previous section and was labelled with [a-32P]dCTP by
using a nick translation labelling kit (Boehringer Mannheim). Washing was done
to a final stringency of 0.83 SSC, 0.1% SDS at 65°C. Fragments of 19.0 and 5.0
kb were detected in HindIII-digested C57BL/6J DNA, and fragments of 15.0,
12.0, 7.3, and 5.0 kb were detected in HindIII-digested M. spretus DNA. The
presence or absence of the 15.0-, 12.0-, and 7.3-kb HindIII M. spretus-specific
fragments, which segregated independently, was monitored in the backcross
mice.
A description of the probes and restriction fragment length polymorphisms
(RFLPs) for the loci used to position the p160 loci in the interspecific backcross
has been reported. These include Ren1 and Fasl, chromosome 1 (66); Myhsf1,
Glut4, and Nf1, chromosome 11 (9, 32); and Hfhbf1 and Sos2, chromosome 12
(3). Recombination distances were calculated as described previously (29) with
the computer program SPRETUS MADNESS. The gene order was determined
by minimizing the number of recombination events required to explain the allele
distribution patterns.
RNA isolation and Northern blot analysis. Total RNA was isolated from adult
mouse tissues or e14 fetuses as described in reference 10. Poly(A)1 RNA was
isolated directly from cultured cells as described previously (26). Total RNA (30
mg) or poly(A)1 RNA (2 mg) was fractionated by formaldehyde-agarose gel
electrophoresis (2). RNA was then transferred to a Hybond-N nylon membrane
(Amersham) as specified by the manufacturer. Northern blots were probed with
a 1.1-kb fragment representing the 59 end of the p160 cDNA (nucleotides 1 to
1083). For probe labelling, hybridization, and washing conditions, see the section
on Southern blotting analysis, above. The blots were stripped and reprobed with
a murine glyceraldehyde-3-phosphate dehydrogenase cDNA fragment.
Cell transfection and infection. The 293T cell line, a derivative of the human
embryonic kidney 293 cell line (16), was used to express p160FLAG, p67*FLAG,
and/or Myb. 293T cells were grown in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal calf serum. Before transfection, the cells were
seeded at 1.4 3 106 in 60-mm culture dishes and left to adhere overnight, after
which the medium was changed. Four hours later, calcium phosphate precipi-
tates prepared as described previously (48), containing 7 mg of pact-p160FLAG
or pact-p67*FLAG DNA, were added for 4 h, after which the cells were
trypsinized and replated onto 100-mm culture dishes. After incubation for 40 to
48 h, total-cell extracts were prepared. Cotransfections of pact-p160FLAG and
pact-WTMyb or L3,4P Myb (38) were performed similarly, except that 3 mg of
each DNA was used, with the total amount of DNA transfected made up to 10
mg with pact vector.
NIH 3T3 cells were infected essentially as described by Pear et al. (57). Briefly,
BOSC 23 retroviral packaging cells were transiently transfected with 10 mg of
pRUFneo-160FLAG by the calcium phosphate procedure. After 24 h, superna-
tants were collected and used to infect NIH 3T3 cells seeded the previous day at
3 3 105 cells/60-mm dish. After an additional 24 h, cells were selected with G418
at 400 mg/ml.
Preparation of cell extracts. Total-cell extracts for GST fusion protein-binding
assays were prepared by lysing the cells in 450 ml of NP-40 lysis buffer (10 mM
Tris-HCl [pH 8.0], 25 mM KCl, 5 mM MgCl2, 0.5% NP-40, 2 mM phenylmeth-
ylsulfonyl fluoride, 40 ml of protease inhibitor cocktail [Boehringer Mannheim]
per ml, 5 mM DTT) plus 500 mM NaCl. Extracts were incubated on ice for 10
min and centrifuged at 45,000 rpm (TLA-45 rotor; Beckman TL-100 ultracen-
trifuge) for 20 min, and the supernatants were removed, aliquoted, and stored at
270°C. Nuclear and cytoplasmic extracts for immunoblotting were prepared
from FDC-P1 and NIH 3T3 cells as described previously (17). Total-cell extracts
for immunoprecipitations were prepared essentially as described by Harlow et al.
(30), with the addition of 10% glycerol.
Binding reactions and immunoprecipitation. 293T total-cell extracts contain-
ing overexpressed p160FLAG and p67*FLAG were used in binding reactions
with GST fusion proteins. These reactions were performed essentially as de-
scribed previously (17). Similarly, for coimmunoprecipitation experiments, 293T
cells were transfected with pact vectors encoding p160FLAG, WT Myb, or L3,4P
Myb as appropriate. Immunoprecipitation from total-cell extracts was performed
essentially as described by Harlow et al. (30), except that the washing buffer
contained 143 mM NaCl. The proteins were analyzed by immunoblotting with
the M2 FLAG monoclonal antibody (IBI) or with anti-Myb monoclonal antibody
1.1 (59). Control immunoprecipitations were carried out with irrelevant mono-
clonal antibodies.
Antibodies and immunoblotting. After SDS-PAGE, proteins were transferred
to a nitrocellulose membrane (Schleicher & Schuell) and blocked in TBS-T (50
mM Tris-HCl [pH 7.4], 135 mM NaCl, 0.1% Tween 20) containing 5% skim milk.
Epitope-tagged proteins were detected by using the M2 FLAG monoclonal
antibody (1:500; IBI), peroxidase-linked anti-mouse immunoglobulin (Ig) (1:
1,000; Amersham), and enhanced chemiluminescence (Pierce).
The GST-p160 59 and 39 fusion constructs (see above) were used to express
amino-terminal and carboxyl-terminal p160 fusion proteins, respectively, and
were purified essentially as described previously (17). The purified GST fusion
proteins, containing p160 amino-terminal residues 1 to 326 or carboxyl-terminal
residues 1046 to 1344, were used to raise polyclonal antisera in rabbits, termed
anti-160N and anti-160C, respectively. The p160 antiserum was used at 1:200
(anti-160N) or 1:500 (anti-160C) for immunoblotting with peroxidase-linked
anti-rabbit Ig (1:1,000) and enhanced chemiluminescence.
Immunofluorescence. NIH 3T3 cells stably infected with pRUFneo-160FLAG
or uninfected cells were seeded at 3 3 104 cells/well of an eight-well chamber
glass slide and left to adhere overnight. After being washed with PBS, the cells
were fixed with ice-cold 50% (vol/vol) methanol-acetone for 30 s and washed
with cold PBS containing 1% bovine serum albumin. The cells were incubated on
ice with primary antibody (anti-FLAG M2 monoclonal antibody [IBI] at 1:300 or
anti-160C [see above] at 1:300) for 45 min. Fluorescein isothiocyanate-conju-
gated secondary antibodies were incubated with the cells on ice for 30 min at the
following dilutions: 1:160 for affinity purified anti-mouse IgG (Silenus) and 1:80
for sheep anti-rabbit Ig F(ab9)2 (Silenus). The cells were mounted with 1%
propylgallate–86% glycerol and viewed under a BioRad MRC 600 confocal
microscope. Digitized images were manipulated with Adobe Photoshop soft-
ware.
Transactivation analysis. Myb transactivation experiments were performed
essentially as described previously (54). Briefly, CV-1 cells were cotransfected
with 4 mg of the chloramphenicol acetyltransferase reporter plasmid, pmycCAT
(51), 4 mg of each of the effector plasmids pact-c-myb or pact-c-mybL34P (38),
various amounts (0 to 5 mg) of pact-160FLAG or pact-p67*FLAG, and 1 mg of
the internal control plasmid pact-b-gal (44). After 48 h, cell extracts were nor-
malized for b-galactosidase activity and assayed for CAT activity.
Nucleotide sequence accession number. The sequence reported here has been
submitted to the GenBank database under accession no. U63648.
RESULTS
Isolation of a p160 cDNA clone. We have described the
detection of p67 and p160 as radiolabelled nuclear proteins
that bound to a bacterially expressed GST fusion protein con-
taining the wild-type Myb leucine zipper region but that failed
to bind to similar fusion proteins bearing a mutated leucine
zipper (17). By scaling up and slightly modifying this proce-
dure, we were able to isolate sufficient p67 from FDC-P1 cells
to allow the generation, purification, and partial amino acid
sequencing of five tryptic peptides (24) (see Materials and
Methods). Comparison of these sequences with protein and
DNA sequence databases indicated that they represented a
novel protein. Degenerate oligonucleotides corresponding to
four of these peptides were used in various combinations as
PCR primers for the amplification of potential p67 coding
sequences from FDC-P1 cDNA (Fig. 1A; also see Materials
and Methods). Nucleotide sequencing of a number of the re-
sultant products identified a 114-bp fragment, generated with
primers corresponding to peptides 4 and 5, that contained an
open reading frame. This sequence encoded residues from
peptide 4 that were not present in the corresponding PCR
primer and also placed a lysine residue immediately preceding
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the N- terminus of peptide 5, which is consistent with its gen-
eration by trypsin cleavage.
An oligonucleotide from within the 114-bp fragment was
then used as a PCR primer to obtain a 459-bp sequence from
a WEHI-3B cDNA library. This fragment also contained an
open reading frame and was used to screen the same library by
hybridization. One clone containing a 3.1-kbp insert was iso-
lated, and the insert was sequenced. This clone contained an
open reading frame encoding 1,010 amino acids which started
with a good match (nucleotides 1115 to 1121) to the Kozak
consensus (A/GNNATGG [40]). However, the predicted mo-
lecular mass of 114 kDa and the in vitro translation product of
;120 kDa (data not shown) were both much larger than p67
but smaller than p160. We therefore explored the possibility
that this clone represented a partial cDNA clone of the p160
mRNA by performing 59 RACE PCR (19) to extend the cloned
sequences. This resulted in an additional ;1 kb of sequence
being identified which, when joined to the 3.1-kb clone, could
encode a predicted protein of 152 kDa, again with sequence
surrounding the initiation codon (nucleotides 13 to 19) con-
forming to the Kozak consensus. The relationship between the
various clones described above is illustrated in Fig. 1A, and the
nucleotide and predicted amino acid sequences are shown in
Fig. 1B. The sequence shown in Fig. 1B may include the 39
terminus of the mRNA since a consensus polyadenlylation
signal (AATAAA; beginning at nucleotide 4106) is present 15
nucleotides before the end of the cloned sequence. To confirm
that the complete sequence does encode p160, the joined
clones were translated in vitro and compared to p160 (and p67)
from FDC-P1 nuclear extracts. The in vitro-translated protein
comigrated with in vivo-labelled p160 on an SDS-polyacryl-
amide gel, and the two proteins showed similar peptide pat-
terns on V8 protease digestion (data not shown).
Features of the predicted p160 sequence. It is apparent from
the predicted p160 amino acid sequence (Fig. 1B) that all five
p67 tryptic peptides are present in the predicted p160 protein
sequence. Inspection of this predicted sequence also indicated
the presence of a highly acidic region in the middle of the
protein and seven short, highly basic sequences embedded in a
proline-serine-rich region at the carboxyl terminus (Fig. 1B).
These basic repeats conform to a consensus Lys-Lys-Xaa-Xaa-
Lys, although some repeats contain arginine instead of lysine at
one position and the Xaa residues are also frequently basic.
Searches for functional motifs indicated the presence of nu-
merous potential phosphorylation sites (not shown), including
those for casein kinase II [(S/T)XX(E/D)] protein kinase C
[(S/T)X(R/K)], p34cdc2 [(S/T)PX(K/R)] (reviewed in reference
39), and MAP kinase [PX(T/S)P] (27). Because p160 and p67
bind to Myb via the leucine zipper region of Myb (17), we
particularly looked for potential leucine zippers within the
predicted p160 sequence. Two regions, residues 307 to 335 and
900 to 928, resemble sequences that could conceivably function
as leucine zippers (see Discussion). In addition, p160 contains
several copies of a recently described motif termed a leucine-
charged domain (LCD) that is involved in interactions between
nuclear hormone receptors and coactivators, possibly by form-
ing a short amphipathic helix (31, 68). Five copies of the core
motif (LXXLL) are present, as well as four possible copies in
which one of the last two leucines is replaced by another
aliphatic amino acid (Fig. 1B).
Searching of nucleic acid and protein sequence databases
revealed that several partial p160 cDNAs have been obtained
by others using essentially random sequencing approaches
(i.e., as expressed-sequence tags). In addition, the deduced
sequence of a protein which is almost certainly the rat homolog
of p160 has recently appeared in the GenPept database (ac-
cession no. U83590). This sequence corresponds to a protein
termed PIP, which was apparently identified as interacting with
PAR transcription factors (see Discussion). Other than this,
homology to sequences of proteins with known functions is
very limited. The highest-scoring sequences are those of the
Drosophila lethal 1B(i) protein (GenBank accession no.
U20542 [69]) and a hypothetical yeast protein of unknown
function (Yelo55cp; GenPept accession no. U18795). Most of
the other (relatively) highly scoring matches, including up-
stream binding factor (UBF) (36), show homology mainly
within the acidic region of p160, suggesting that the database
search has preferentially identified a subset of proteins with
highly acidic regions (see Discussion).
Chromosomal localization of the p160 gene and related se-
quences. Since the p160 cDNA sequence appeared to repre-
sent a novel gene, it was of interest to determine its chromo-
somal location and thus to determine whether it maps to a
locus corresponding to a previously identified mouse mutant.
This in turn could provide a clue to the function of the gene.
Initial Southern analysis of genomic p160 sequences carried
out with probes corresponding to both the 59 and 39 ends of the
p160 cDNA (Fig. 2A) detected three or more hybridizing
bands with each probe, suggesting that there may be more than
one p160-related gene.
Chromosomal localization was carried out by Southern hy-
bridisation of the 39 probe to DNA from a panel of interspe-
cific (Mus musculus 3 M. spretus) backcrosses (12). RFLPs
between the two species were used to monitor the segregation
of p160-related M. spretus sequences in the backcross mice.
The results of this analysis, illustrated in Fig. 2B, indicate that
there are three loci which contain p160-related sequences on
chromosomes 1, 11, and 12. Although three (or more) frag-
ments could be detected with the 59 probe with most restriction
enzymes (Fig. 2A), only one RFLP could be identified, which
allowed the corresponding fragment to be mapped to chromo-
some 11 (data not shown). Since this band did not show re-
combination with the chromosome 11 fragment detected with
the 39 probe (data not shown), both fragments presumably
FIG. 1. Molecular cloning, nucleotide sequence, and predicted amino acid
sequence of p160 (see Materials and Methods for details). (A) Overlapping
cDNA clones that comprise the p160 cDNA and location of p67-derived peptide
sequences. The top four (open) boxes represent cDNA clones derived by PCR,
library screening, or 59-RACE PCR as indicated. The bottom box (shaded)
represents the entire sequence and shows the locations of the sequences corre-
sponding to the five p67-derived tryptic peptides (solid boxes). (B) Nucleotide
sequence of p160 cDNA and predicted amino acid sequence of p160. The
p67-derived tryptic peptide sequences are underlined and bold, the acidic region
is boxed, and the basic repeats are italicized and bold (Note that two of these
sequences contain overlapping repeat motifs, while that starting at residue 1332
is incomplete.) Potential LCD motifs are indicated by dashed overlining. The
symbol 'Á indicates the carboxyl terminus of p67*.
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represent the same locus. Moreover, we have found that an
intron probe, derived from genomic clones that correspond in
sequence to at least 2,067 bp of the p160 cDNA, also maps to
chromosome 11 and cosegregates with the locus identified with
the other probes (data not shown). We have therefore termed
the chromosome 11 locus P160, since it appears to represent
the entire p160 cDNA sequence, and have termed the loci on
chromosomes 1 and 12 P160-rs1 and P160-rs2 (where rs stands
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for “related sequence”), respectively. The lack of further
RFLPs with the 59 probe did not allow us to determine whether
or not the P160-rs1 and P160-rs2 loci also contain 59 p160-
related sequences.
Expression of p160 mRNA. The cloned p160 cDNA se-
quence was used to identify and examine the expression of
p160 mRNA. Northern blotting of polyadenylated RNA from
a number of cell lines with a probe corresponding to the 59-
most 1 kb of p160 (Fig. 3A) or with the entire p160 cDNA
(data not shown) revealed a single mRNA species of ;4.5 kb
in each murine cell line. The size of this transcript is clearly
adequate to include all of the cloned sequences (4.1 kb) and a
poly(A) tract. Furthermore, the ubiquitous expression of the
4.5-kb mRNA corresponds to the previously determined dis-
tribution of p160 (17). Importantly, no additional mRNA spe-
cies were present in cells (such as FDC-P1 and WEHI-3B) that
also expressed p67 (17). Therefore, there does not appear to
be a separate transcript that could encode p67 (see below).
Note also that the p160 cDNA did not detect a transcript in
RNA from the human HL-60 cell line; this is consistent with
our previous failure to detect p160 or p67 in human cells
(including HL-60) by our standard binding assay (17).
We also examined the expression of p160 mRNA in a num-
ber of different tissues and organs of the mouse. Figure 3B
shows that p160 is expressed in most tissues and organs; more-
over, in other experiments, expression was detected in the
FIG. 2. Genomic organization and chromosomal localization of P160 and the
related genes, P160-rs1 and P160-rs2. (A) Southern blot analysis of murine DNA
with probes corresponding to the 59-most 1.0 kb (left) and the 39-most 1.0 kb
(right) of the p160 cDNA sequence. DNA was digested with the following
restriction endonucleases: lanes 1 and 6, XbaI; lanes 2 and 7, SacI; lanes 3 and
8, PstI; lanes 4 and 9, HindIII; lanes 5 and 10, EcoRI. The positions and sizes (in
kilobases) of DNA markers are shown at the left. (B) Summary of chromosomal
localization of p160-related loci in the mouse genome, as determined by inter-
specific backcross analysis. The grids above each chromosome map represent the
possible genotypes of the backcross mice, with solid squares representing the M.
spretus alleles and open squares representing the M. musculus alleles; the num-
bers of recombinants of the indicated genotypes are shown below the grid. The
number of recombinant N2 animals over the total number of N2 animals is
shown at the left of each chromosome map. The recombination frequencies
between each P160-related locus and the adjacent markers, expressed as genetic
distance in centimorgans (61 standard error), are also shown. The positions of
corresponding loci on human chromosomes, where known, are shown at the right
of each chromosome map.
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spleen, liver, intestines, and lungs (data not shown). Interest-
ingly, the level in fetal liver is particularly high; this probably
does not indicate preferential expression in hematopoietic tis-
sue, since expression in bone marrow is much lower. Moreover,
expression is not substantially greater in hematopoietic cell
lines than in fibroblasts (Fig. 3A).
Generation of antisera that recognize p160 and p67. To
generate a reagent for the detection of p160 (and p67), anti-
sera were raised against GST fusion proteins containing the
N-terminal 326 residues and C-terminal 298 residues of p160.
These were then used to probe nuclear and cytoplasmic ex-
tracts of FDC-P1 and NIH 3T3 cells. Figure 4 shows that, as
expected from our previous work (17), the N-terminal anti-
serum (anti-160N) recognized proteins of 160 and 67 kDa in
nuclear but not cytoplasmic extracts from FDC-P1 cells. Also
as expected from our previous report (17), p160 but not p67
was detected in NIH 3T3 nuclear extracts. In contrast, the
C-terminal antiserum (anti-160C) detected only p160 in nu-
clear but not cytoplasmic extracts from both cell types. More-
over, each antiserum detected the same proteins following
binding of nuclear extracts to GST fusion proteins containing
the Myb NRD (data not shown). Other bands (of ;97 and
;110 kDa) detected by the antisera may be due to nonspecific
FIG. 3. Northern blot analysis of p160 mRNA expression with the p160 cDNA probe. In the upper panels, 2 mg of poly(A)1 RNA from the indicated cell lines was
loaded in each lane (MTHC, myb transformed hemopoietic cells) (A) or 30 mg of total RNA from the indicated mouse tissues (or FDC-P1 cells) was loaded in each
lane (B). The size of the p160 mRNA was determined by comparison with RNA markers (not shown). In the lower panels, the Northern blots shown in the upper panels
were stripped and reprobed with a glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA as a control for mRNA loading; only the relevant area of each blot
is shown.
FIG. 4. Proteins detected by antisera raised to the N and C termini of p160.
Cytoplasmic (Cyt) and nuclear (Nuc) extracts from FDC-P1 and NIH 3T3 cells,
as indicated, were fractionated by SDS-PAGE and immunoblotted with antisera
against the N-terminal (anti-160N) (A) or the C-terminal (anti-160C) (B) regions
of p160. The positions of p160 and p67 are indicated by arrows, and those of size
standards (in kilodaltons) are indicated at the left.
FIG. 5. Proteolysis of p160 by cell extracts. In vitro-translated p160 labelled
with [35S]methionine was incubated with extracts from FDC-P1 or NIH 3T3 cells
for the indicated times (in minutes), after which the products were analyzed by
SDS-PAGE. The positions and molecular masses of size standards are indicated
at the right, and the bands corresponding to p160 and the 67-kDa product (p67)
are indicated at the left.
VOL. 18, 1998 CLONING OF THE p160 Myb-BINDING PROTEIN 995
 o
n
 O
ctober 26, 2015 by University of Queensland Library
http://m
cb.asm
.org/
D
ow
nloaded from
 
reactivities; however, it is also possible that they represent
other p160-related proteins.
p67 represents an N-terminal proteolytic cleavage product
of p160. The clones described here (Fig. 1) were isolated on the
basis of peptide sequences derived from p67, but in fact they
encode p160 (see also below). While this is compatible with the
observation that the two proteins are related, as judged by V8
protease peptide mapping (17), it is apparent from the se-
quence that the N-terminal portion of p160 contains all five of
the tryptic peptides that were derived from p67 (Fig. 1B).
Moreover, we show above that the anti-160N antiserum but
not the anti-160C antiserum also reacts with p67 (Fig. 4).
These observations led us to suspect that p67 is the N-terminal
proteolytic cleavage product of p160. The existence of a single
mRNA species corresponding to p160 in cells such as FDC-P1
and WEHI-3B that express both p160 and p67 (Fig. 3A) is also
consistent with this notion; if p67 were derived from an alter-
natively spliced transcript or another gene, we might expect to
find an additional mRNA species.
If p67 is generated by proteolysis, cells in which p67 is
detected should contain a proteolytic activity capable of cleav-
ing p160, while this activity should be absent from cells that do
not contain detectable p67. This prediction was tested by in-
cubating radiolabelled in vitro-translated p160 with FDC-P1
and NIH 3T3 cell extracts. Figure 5 shows that the FDC-P1
extract generated a number of cleavage products, including
one with an apparent molecular mass of ca. 67 kDa. Moreover,
this protein represents the N-terminal portion of p160 since it
could be immunoprecipitated with the anti-160N antiserum
described above (data not shown). In contrast, the NIH 3T3
extract failed to cleave p160 even after extended incubation
(Fig. 5).
Binding properties of full-length and truncated forms of
p160. To examine the binding properties of the protein(s)
encoded by the p160 cDNA clone, we constructed a carboxyl-
truncated form of p160, which we term p67*, by inserting a
termination codon after nucleotide 1755 (Fig. 1B), resulting in
a 580-amino-acid protein with a predicted molecular mass of
ca. 67 kDa (this construct was initially made to approximate
the endogenous p67 protein). Epitope-tagged versions of p160
and p67* were then constructed by adding a sequence encod-
ing the FLAG epitope (33) to the 59 ends of each cDNA
construct. These constructs were inserted into the pact expres-
sion vector (54) and transiently transfected into human embry-
onic kidney 293T cells. Cell extracts were then analyzed di-
rectly by immunoblotting with anti-FLAG antibodies (Fig. 6A)
FIG. 6. Expression and binding properties of p160FLAG and p67*FLAG following transfection into 293T cells. In each panel, proteins were detected by
immunoblotting with anti-FLAG monoclonal antibody M2. (A) SDS-PAGE of extracts from cells transfected with pact expression vectors containing p160FLAG,
p67*FLAG constructs, or mock-transfected cells, as indicated. (B) Analysis of bound and unbound p160FLAG and p67*FLAG following incubation of the cell extracts
shown in panel A with Sepharose beads carrying the GST-NRD2 (lanes M), GST-L3,4P (lanes M9), or GST-Jun (lanes J) fusion proteins. Note that only 50% of each
unbound fraction was loaded.
FIG. 7. Coimmunoprecipitation of Myb and p160. Extracts from 293T cells cotransfected with expression vectors encoding p160FLAG, wild-type Myb (Myb), L3,4P
mutant Myb (L3,4PMyb), or combinations of these as indicated were subject to immunoprecipitation with anti-FLAG antibodies. The resultant immunoprecipitates
were then analyzed by SDS-PAGE and immunoblotting with anti-Myb monoclonal antibody 1.1. The immunoblots were then stripped and reprobed with M2
anti-FLAG antibodies. Also shown is a direct immunoblot of a portion of each cell lysate used for immunoprecipitation (Cell Lysate).
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or following binding reactions with GST fusion proteins con-
taining Myb or Jun leucine zipper regions (Fig. 6B). In agree-
ment with the properties of endogenous p160 and p67 (17),
FLAG-tagged p160 and p67* both bound to the GST-NRD2
protein, which contains a wild-type Myb leucine zipper region,
but not to the GST-L3,4P (17) protein, which has a mutated
leucine zipper. Interestingly, it appears that p67* binds more
efficiently than p160 to GST-NRD2 (compare the “bound” and
“unbound” lanes in Fig. 6B). Also in agreement with studies of
the endogenous proteins, p160FLAG bound to the GST-Jun
protein which carries the leucine zipper and basic regions of
c-Jun whereas p67*FLAG did not. These observations further
validate the authenticity of the p160 cDNA clone and show
that a truncated version of p160, i.e., p67*, has similar binding
properties to p67.
To determine whether full-length p160 and c-Myb proteins
could interact in the intracellular milieu, we used expression
vectors encoding wild-type c-Myb or the L3,4P leucine zipper
mutant and p160FLAG to coexpress these proteins in 293T
cells. Cell extracts were then subjected to immunoprecipitation
with anti-FLAG antibodies, and the immunoprecipitates were
analyzed by immunoblotting with anti-FLAG and anti-Myb
antibodies. Figure 7 shows that anti-FLAG immunoprecipi-
tates from cells expressing both p160 and c-Myb contained WT
c-Myb protein while those from transfections of p160FLAG or
Myb alone did not. Neither protein was precipitated when an
irrelevant control antibody was used (data not shown). More-
over, Fig. 7 shows that, in contrast to WT c-Myb, the leucine
zipper mutant did not interact specifically with p160FLAG.
The small amount of Myb detected in the immunoprecipitate
FIG. 8. Effect of p160 and p67* on transactivation by wild-type (WT) and L3,4P mutant (Mut) Myb. (A) CAT activity (measured by thin-layer chromatography)
in CV-1 cells transfected with the pc-myc-CAT reporter plasmid, pact-b-galactosidase, and pact expression vectors encoding Myb, p160FLAG, or p67*FLAG, as
indicated at the bottom of the chromatograms. Where the p160FLAG or p67*FLAG vector was included, the amount of plasmid used (in micrograms) is shown. The
degree of activation, expressed as the ratio of CAT activity obtained in each transfection compared to that in the control transfection with no Myb vector (leftmost lane),
is shown above each lane; these values are normalized with respect to b-galactosidase activity to correct for differences in transfection efficiency. See Materials and
Methods for details. (B) Representation of the data from panel A to indicate the degree of inhibition of Myb-stimulated transactivation by p160 and p67*, which is
taken as 100% for each form of Myb (WT or MUT, as indicated). Error bars represent the standard error as determined from triplicate transfections.
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from the p160FLAG-plus-L3,4P Myb cotransfection probably
reflects a degree of “stickiness” of the latter protein, since a
similar amount was observed in precipitates from cells trans-
fected with L3,4P Myb alone. These data confirm that full-
length c-Myb and p160 can indeed associate specifically in vivo
and that their association requires the c-Myb leucine zipper
motif.
p67* but not p160 inhibits transactivation by Myb. Since the
original rationale for isolating proteins that interact with the
Myb leucine zipper was that such proteins may be inhibitors of
FIG. 9. Immunofluorescence analysis of the subcellular localization of p160. Each panel shows phase-contrast (left) and fluorescence (right) images of the same field
of cells. The cells shown in panels A to C are NIH 3T3 fibroblasts, and those shown in panel D are NIH 3T3 fibroblasts expressing p160FLAG (see the text for details).
These were stained with pre-immune rabbit serum (A), 160C rabbit antiserum (B), and anti-FLAG monoclonal antibody M2 (C and D).
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Myb function, we examined the effects of p160 on one of the
key activities of Myb, i.e., its ability to enhance transcription
from promoters containing Myb-binding sites. p67* was also
tested in this assay, since although it can interact with the Myb
leucine zipper (Fig. 6), it presumably lacks other functional
domains of p160 and thus may have had the potential to act as
a dominant negative antagonist of p160 function. For this pur-
pose, we used the c-myc promoter region coupled to the chlor-
amphenicol acetyltransferase reporter gene (51, 54). This con-
struct was cotransfected into CV-1 cells along with expression
vectors for either wild-type or leucine zipper-mutated (L3,4P)
Myb and with various amounts of p67* or p160 expression
vector. Note that as expected (38), a greater degree of trans-
activation was observed when cells were transfected with the
leucine zipper-mutated Myb (Fig. 8A). Figure 8B shows that
increasing amounts of p67* substantially inhibited transactiva-
tion by wild-type Myb, down to a level of just 12% of that
obtained in the absence of p67*. On the other hand, p160 had
relatively little effect, giving a slight stimulation at low levels
and a slight (25%) inhibition at the highest level. Most of the
inhibition by p67* was dependent on the Myb leucine zipper,
although nearly 50% inhibition of transactivation by L3,4P
Myb was obtained with the highest level of p67*. Again, p160
had little effect on transactivation by the mutant form of Myb
(Fig. 8). These results are unlikely to reflect a nonspecific
suppression of transcriptional activity, because expression of
the control reporter construct (pact-b-galactosidase) showed
no inhibition by p67* or p160 (data not shown).
p160 is a predominantly nucleolar protein. The subcellular
localization of p160 was further examined by using the p160
antisera described above in immunofluorescence studies on
NIH 3T3 fibroblasts. To our surprise, staining with the 160C
antiserum revealed that p160 is located predominantly in the
nucleolus (Fig. 9B), although, significantly (see Discussion),
some nucleoplasmic staining was also evident. To indepen-
dently confirm this observation, we examined NIH 3T3 fibro-
blasts that had been infected with a retroviral vector encoding
p160FLAG. Again, staining with monoclonal anti-FLAG anti-
body showed predominantly nucleolar localization (Fig. 9D).
DISCUSSION
Features of the p160 protein. We report here the molecular
cloning of cDNA corresponding to p160, one of two nuclear
proteins that were identified by their ability to bind to the
c-Myb-negative regulatory domain and, specifically, to the
leucine zipper motif within this domain (17). Although the
p160 cDNA was isolated on the basis of peptide sequences
derived from p67, evidence based on size, peptide mapping,
mRNA expression pattern, and the binding specificity of its
translation product demonstrates that the cDNA represents
p160.
The predicted p160 amino acid sequence is novel and shows
no close homology to other sequences present in databases
other than the presumptive rat homolog (GenPept accession
no. U83590); this sequence may represent a partial clone since
it lacks the first 67 residues of the mouse protein. Many of the
other higher-scoring matches show homology only to the acidic
region of the protein (data not shown), which casts some doubt
on the biological significance of such similarities. However, the
similarities between p160 and the highest-scoring match, the
product of the Drosophila lethal 1B(i) gene, extend beyond this
region and may be of more significance (see below).
Inspection of the predicted p160 sequence reveals some
potentially interesting features (see Results and Fig. 1). As
mentioned above, there are two leucine zipper-like sequences,
starting at amino acids 307 and 900, with the following residues
in a possible heptad repeat: L-L-L-I-M and L-L-Q-L-L. How-
ever, mutagenesis of this region, which replaced two leucine
residues in each of these sequences with prolines, had no effect
on the ability of p160 to bind to the Myb or Jun leucine zipper
regions (39a). Thus, the structures that mediate the interaction
of p160 with Myb and Jun remain to be identified; one intrigu-
ing possibility is that these interactions involve some of the
LCD motifs. Our results do show, however, that the Myb
leucine zipper- and Jun bZip domain-binding regions of p160
are distinct. The Myb-binding region must lie within the first
580 amino acids, since p67*, like endogenous p67, efficiently
and specifically binds to the Myb leucine zipper; similarly, the
Jun-binding region is carboxy-terminal of residue 580 because
p67* fails to bind the Jun leucine zipper region. The functions
of the other structurally distinguishable regions of p160, i.e.,
the highly acidic region in the center of the protein and the
basic repeats at the C terminus, are currently uncertain. It is
possible that the acidic region indicates a function in transcrip-
tional regulation, since many transcription factors have acidic
transactivation domains (65). It is also interesting that the basic
repeats bear a close similarity to nuclear localization signals
(reviewed in references 20 and 35), and, indeed, preliminary
data suggest that their deletion results in the cytoplasmic lo-
calization of at least a proportion of the protein, which, as we
show here (Fig. 4), is normally exclusively nuclear (20a).
Relationship between p160 and p67. Earlier data clearly
showed that p160 and p67 are functionally and structurally
related since they both bind the c-Myb leucine zipper and
share many peptides generated by partial digestion with V8
protease (17). The present work extends those results and
provides several lines of evidence that p67 is generated by
proteolysis of p160. This raises the possibility that, despite its
reproducibility and strict cell type specificity, the detection of
p67 in nuclear extracts is a consequence of the nuclear isola-
tion procedure. In fact, little of this protein is detected when
whole cells are lysed directly in the presence of SDS (66a).
Nevertheless, it is conceivable that there may be physiological
conditions that also activate or release the protease which
cleaves p160. This, in turn, could have biological consequences,
since p67, like the p67* construct, may similarly function as an
inhibitor of transactivation by Myb. Examination of the effects
of various cell treatments, e.g., growth factor deprivation or
induction of differentiation, on the generation of p67 will be
required to resolve this issue.
Similarities of p160 to other nucleolar proteins and possible
implications for p160 function. An unexpected finding from
this study was the nucleolar localization of p160. Although this
was not anticipated for a potential regulator of c-Myb activity,
since Myb is not detected in the nucleolus (4), this observation
is consistent with the homology between p160 and the product
of the Drosophila lethal 1B(i) gene (69) (GenBank accession
no. U20542). Unfortunately, little information is available
about the function of this gene, but, interestingly, its product is
reportedly also a nucleolar protein (cited in the GenBank
entry), as is PIP, the presumptive rat homolog of p160 (again,
as cited in the GenPept entry). It may also be of significance
that one of the other higher-scoring matches from BLAST
searches of protein databases is UBF (36). UBF is a polymer-
ase I transcription factor and thus is also a nucleolar protein.
As remarked above, homology to p160 is mostly within the
acidic region, but it is of interest that the acidic region of UBF
is essential for its transactivating/antirepressing capacity and is
involved in displacing histones from DNA (41, 42). Another
nucleolar protein, Nopp140 (45, 46), also shows some other
general similarities to p160, although there is no significant
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sequence homology. Like p160, Nopp140 also has an acidic
region containing multiple casein kinase II phosphorylation
sites and multiple, basic nuclear localization signal-like se-
quences toward its C terminus (46). Although Nopp140 is
predominantly nucleolar, it was noted that a small proportion
of Nopp140 can be detected in the nucleoplasm (46), as also
seen here with p160. The significance of this has been high-
lighted by a recent report (47) that Nopp140 can function as a
transcriptional coactivator of the bZip transcription factor
C/EBPb in stimulating the transcription of a polymerase II-
transcribed gene. Thus, the similarities between p160 and
Nopp140 (and between p160 and UBF) raise the possibility
that p160 plays a role, e.g., as a coactivator, in the transcription
of both polymerase I- and some polymerase II-transcribed
genes. In this light, the predominantly nucleolar localization of
p160 can be reconciled with its interaction with Myb, Jun, and
possibly other transcription factors; i.e., the small fraction of
p160 in the nucleoplasm may be involved in such interactions.
This notion is further supported by the reported (i.e., as stated
in the GenPept entry) identification of the presumptive rat
homolog of p160, PIP, by its interaction with members of the
PAR family of transcription factors. Moreover, the presence of
several LCD motifs, which have recently been reported to
mediate the interaction between certain coactivators and nu-
clear hormone receptors (31, 68), is also consistent with a role
for p160 in the regulation of polymerase II-mediated transcrip-
tion.
Effects of p67* and p160 on transactivation by Myb. Al-
though overexpression of p160 had no significant effect on
transactivation by Myb, our findings remain consistent with a
role for p160 as a potential cofactor in Myb-regulated tran-
scription. It may simply be that the levels of endogenous p160
in CV-1 cells are sufficiently high as not to be rate-limiting, so
that excess p160 has little or no effect (a similar observation
was made for p/CIP [68]). On the other hand, inhibition by a
truncated form of p160, i.e., p67*, supports a role for p160 in
transcriptional regulation by Myb. One possible mechanism is,
as we envisaged, that p67* is acting as a dominant negative
antagonist of a coactivator function of (endogenous) p160,
since it lacks many of the potential functional domains of the
latter. Alternatively, truncation may unmask or enhance an
inhibitory function of p160 that is normally subject to regula-
tion (e.g., by phosphorylation or by other protein-protein in-
teractions). In any case, while the precise mechanism of inhi-
bition remains to be defined, it almost certainly involves
binding to Myb via the leucine zipper motif of Myb, since
inhibition of transactivation by p67* is largely dependent on
the integrity of this motif. (A small [;50%] inhibition of trans-
activation by mutant [L3,4P] Myb was consistently observed
upon cotransfection with p67*. Two possible explanations for
this are that p67* can interact with another region of c-Myb in
addition to the leucine zipper, and/or that it has a more general
transcriptional repressor activity, due for example to interac-
tions with other transcription factors.)
If p160 does function as a coregulator of c-Myb-mediated
transcription, it would represent a third such protein known to
interact with Myb, since CREB-binding protein (CBP) (13, 56)
and p100 (14) have already been shown to do so. These may
function together as part of a transcription complex; alterna-
tively, there may be some exclusivity in these interactions. The
net effect of all of the possible interactions may be complex and
difficult to predict. For example, p100 appears to repress trans-
activation by Myb (14), yet it was originally identified as a
transcriptional coactivator (67). Moreover, while p160 has at
least some characteristics of a transcriptional coactivator (see
above), it binds to a region of c-Myb that is involved in negative
regulation. It is possible that in vivo, these potential regulators
differentially affect transcription of various Myb “target
genes”; for instance, p160 may be required for Myb to enhance
the transcription of a subset of target genes involved in the
function of mature hemopoietic cells but not required for its
transforming effects (see the discussion of target genes in ref-
erence 52).
Expression of p160. The expression of p160 mRNA corre-
sponds to that of p160 as detected by binding to GST-Myb
fusion protein in a series of cell lines (17). Our present work
extends the analysis of expression to a range of tissues and
organs; together, these data suggest that p160 is present in
most or all cell types. Therefore, we might suspect that p160
serves a function or functions required in all cell types. This is
consistent with a role in rRNA synthesis, as suggested by its
nucleolar localization, and also with its potential to interact
with c-Jun, which is expressed more widely than in the limited
range of cells that express c-Myb. The high level of expression
in fetal liver, which is a very active site of cell proliferation, is
similarly consistent with a role in rRNA synthesis. Neither of
these possibilities excludes a role in interacting with c-Myb; in
fact, the high p160 level in fetal liver, which is enriched for
hematopoietic progenitor cells that express c-Myb, is also com-
patible with this role.
Chromosomal localization of the p160 gene. Finally, we
should consider the potential significance of the presence in
the mouse genome of three loci that hybridize with the p160
cDNA. We have termed the chromosome 11 locus P160 be-
cause it contains sequences related to both the 59 and 39 ends
of the p160 cDNA and because genomic clones that map to
this locus correspond in sequence to the cDNA. Furthermore,
by exploiting the weak cross-reaction of mouse p160 cDNA
with human genomic sequences (which was not sufficient to
allow detection of human p160 mRNA [Fig. 3A]), we have
identified a human P160 homolog located in a syntenic region
of the human genome (39b). Thus, it is highly unlikely that one
of the other loci (P160-rs1 or P160-rs2) contains the sequence
which we have cloned. It is somewhat surprising that we did not
detect other transcripts that could correspond to the other
P160-related loci; this might indicate that all the transcripts are
of the same size or that expression of the related genes is much
more restricted. However, it should also be borne in mind that
one (or both) of these loci could represent a pseudogene(s).
The existence of the three P160-related genes complicates
the identification of potential correlations between these genes
and loci corresponding to mutant phenotypes. Without know-
ing the precise functions of p67 and p160, it is unclear what
kinds of phenotypes one might expect. However, the ability of
p160 and p67 to interact with the NRD of c-Myb raises the
possibility that P160 potentially acts as a tumor suppressor
gene. To the best of our knowledge, there are no obvious
murine mutants which exhibit neoplastic or preneoplastic phe-
notypes that map close to any of the three P160 loci. Current
studies on the human homolog of P160 (39a), together with the
studies on the activities of murine p160 with the reagents
described in this report, should help to determine whether
lesions in P160 play a role in human disease.
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